CarGurus forecasts fourth-quarter revenue of $258.5 million to $263.5 million
Bitget2026/11/05 22:46- CarGurus forecasts full-year 2026 revenue of $1.01 billion-$1.02 billion, representing growth of 11.5%-12.1%.
- Full-year adjusted EBITDA from continuing operations is projected at $347.5 million-$355.5 million; non-GAAP EPS is expected at $2.66-$2.72.
- Fourth-quarter revenue is forecast at $258.5 million-$263.5 million, with adjusted EBITDA from continuing operations of $93 million-$101 million.
- Non-GAAP EPS from continuing operations is expected to reach $0.73-$0.79.
- Third-quarter revenue from continuing operations rose 12% year over year, with an adjusted EBITDA margin of 35%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
